Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.

ABSTRACT:

Background

Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients.

Methods

Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was

SUBMITTER: Martin-Romano P 

PROVIDER: S-EPMC6508715 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature